curcumin has been researched along with Chagas-Disease* in 3 studies
3 other study(ies) available for curcumin and Chagas-Disease
Article | Year |
---|---|
Pyrazol(in)e derivatives of curcumin analogs as a new class of anti-
Topics: Animals; Chagas Disease; Curcumin; Cyclization; Diarylheptanoids; Drug Evaluation, Preclinical; Enzyme Inhibitors; Humans; Hydrazines; Macrophages; Mice; Molecular Docking Simulation; Parasitic Sensitivity Tests; Protein Binding; Pyrazoles; Structure-Activity Relationship; Triose-Phosphate Isomerase; Trypanocidal Agents; Trypanosoma cruzi | 2021 |
Curcumin Enhances the Anti-Trypanosoma cruzi Activity of Benznidazole-Based Chemotherapy in Acute Experimental Chagas Disease.
Although curcumin can increase the effectiveness of drugs against malaria, combination therapies using the molecule have never been investigated in Chagas disease (ChD). Therefore, we evaluated the efficacy of curcumin as a complementary strategy to benznidazole (Bz)-based chemotherapy in mice acutely infected with Trypanosoma cruzi Eighty-four 12-week-old Swiss mice were equally randomized into seven groups: uninfected (NI), T. cruzi infected and untreated (INF), infected and treated with 100 mg/kg of body weight Bz (B100), 50 mg/kg Bz (B50), 100 mg/kg curcumin (C100), 100 mg/kg Bz plus 100 mg/kg curcumin (B100 plus C100), and 50 mg/kg Bz plus 100 mg/kg curcumin (B50 plus C100). After microscopic identification of blood trypomastigotes (4 days after inoculation), both drugs were administered by gavage once a day for 20 days. Curcumin showed limited antiparasitic, anti-inflammatory, and antioxidant effects when administered alone. When curcumin and Bz were combined, there was a drastic reduction in parasitemia, parasite load, mortality, anti-T. cruzi IgG reactivity, circulating levels of cytokines (gamma interferon [IFN-γ], interleukin 4 [IL-4], and MIP1-α), myocardial inflammation, and morphological and oxidative cardiac injury; these results exceeded the isolated effects of Bz. The combination of Bz and curcumin was also effective at mitigating liver toxicity triggered by Bz, increasing the parasitological cure rate, and preventing infection recrudescence in noncured animals, even when the animals were treated with 50% of the recommended therapeutic dose of Bz. By limiting the toxic effects of Bz and enhancing its antiparasitic efficiency, the combination of the drug with curcumin may be a relevant therapeutic strategy that is possibly better tolerated in ChD treatment than Bz-based monotherapy. Topics: Acute Disease; Animals; Chagas Disease; Curcumin; Cytokines; Female; Liver; Mice; Myocardium; Nitroimidazoles; Parasitemia; Transaminases; Trypanocidal Agents; Trypanosoma cruzi | 2016 |
Curcumin treatment provides protection against Trypanosoma cruzi infection.
Trypanosoma cruzi, the etiologic agent of Chagas disease, causes an acute myocarditis and chronic cardiomyopathy. The current therapeutic agents for this disease are not always effective and often have severe side effects. Curcumin, a plant polyphenol, has demonstrated a wide range of potential therapeutic effects. In this study, we examined the effect of curcumin on T. cruzi infection in vitro and in vivo. Curcumin pretreatment of fibroblasts inhibited parasite invasion. Treatment reduced the expression of the low density lipoprotein receptor, which is involved in T. cruzi host cell invasion. Curcumin treatment of T. cruzi-infected CD1 mice reduced parasitemia and decreased the parasitism of infected heart tissue. This was associated with a significant reduction in macrophage infiltration and inflammation in both the heart and liver; moreover, curcumin-treated infected mice displayed a 100% survival rate in contrast to the 60% survival rate commonly observed in untreated infected mice. These data are consistent with curcumin modulating infection-induced changes in signaling pathways involved in inflammation, oxidative stress, and apoptosis. These data suggest that curcumin and its derivatives could be a suitable drug for the amelioration of chagasic heart disease. Topics: Animals; Antiprotozoal Agents; Cells, Cultured; Chagas Disease; Curcumin; Disease Models, Animal; Fibroblasts; Heart; Humans; Liver; Macrophages; Male; Mice; Myocardium; Parasitemia; Survival Analysis; Treatment Outcome; Trypanosoma cruzi | 2012 |